Record Details

[Pegylation and interferons in multiple sclerosis]

Farmeconomia

View Archive Info
 
 
Field Value
 
Title [Pegylation and interferons in multiple sclerosis]
 
Creator Centonze, Diego
Puma, Elisa
Saleri, Cecilia
Vestri, Giulia
Iannazzo, Sergio
Santoni, Laura
Giuliani, Luigi
Canonico, Pier Luigi
 
Subject —
PEG; Interferon beta-1a; Plegridy; Half-life
 
Description Pegylation is a procedure used for drug development since the 1970s and consists of the conjugation of a polyethylene glycol molecule (PEG) to a drug. PEG has shown to be safe and effective in improving the pharmacokinetic and pharmacodynamic profile of drugs. Recently, a 20 kDa linear chain of PEG was conjugated to interferon beta-1a with the aim to offer a new treatment option to relapsing-remitting multiple sclerosis (RRMS) patients. Due to a prolonged bioavailability, this new drug can be administered less frequently (every two weeks) than the other interferons beta available, thus allowing to hypothesize a better adherence to the treatment, which, in turn, should result in better clinical and economic outcomes. A phase III clinical trial has proven its effectiveness compared to placebo in RRMS patients, as well as a safety profile comparable to that found in other interferon beta preparations. The immunogenicity of this new molecule is < 1%, thus minimizing the suppression or reduction of interferon beta biological activity that could come from the development of Neutralizing Antibodies (NAbs).[Article in Italian]
 
Publisher SEEd Medical Publishers
 
Contributor —
 
Date 2016-07-26
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
 
Format text/html
application/pdf
 
Identifier http://journals.edizioniseed.it/index.php/FE/article/view/1229
10.7175/fe.v17i2S.1229
 
Source Farmeconomia. Health economics and therapeutic pathways; Vol 17, No 2S (2016); 5-11
2240-256X
1721-6915
 
Language eng
 
Relation http://journals.edizioniseed.it/index.php/FE/article/view/1229/1553
http://journals.edizioniseed.it/index.php/FE/article/view/1229/1554
 
Coverage —
—
—
 
Rights Copyright (c) 2016 Farmeconomia. Health economics and therapeutic pathways
http://creativecommons.org/licenses/by-nc/4.0